FDA Approves Labeling Changes For Long-Acting Opioids

Published Online: Monday, May 12, 2014
The FDA announced on April 16, 2014, that it has approved classwide labeling changes for all extended-release and long-acting (ER/LA) opioid analgesics. The changes were originally announced in September 2013.

The updated indication for the medications states that they are indicated for pain severe enough to require daily, around-the-clock long-term opioid treatment for which alternative therapies are inadequate. Due to the risk of addiction, abuse, and misuse of ER/LA opioid analgesics, the FDA notes that they should be reserved for patients in whom alternatives such as nonopioid analgesics or immediate-release opioids have been not tolerated or ineffective in managing pain.

In addition, ER/LA opioid analgesics will need to bear a new boxed warning cautioning that long-term maternal use during pregnancy can lead to neonatal opioid withdrawal syndrome, which can be life-threatening.

According to the FDA, its goal in requiring the labeling changes is to reduce the risks of ER/LA opioid analgesics while maintaining appropriate access to those who need them to manage pain.

Latest Articles
Donnie Calhoun, RPh, PD, National Community Pharmacists Association (NCPA) Foundation vice president, discusses how pharmacists can prepare themselves and their business before, during, and after a disaster.
Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, talks about some new transactions available that can help pharmacists.
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Bryan Ziegler, PharmD, executive director of Kennedy Pharmacy Innovation Center, provides some resources for community pharmacists to use when implementing new collaborative services with primary care providers.
Latest Issues